PExA AB is pleased to announce that The Prince Charles Hospital Foundation (TPCHF) in Brisbane, Australia, has signed a 12-month rental agreement for the PExA 2.1 research instrument. The agreement, which includes both rental and formalized data sharing, follows an earlier evaluation phase during which the technology was used to collect samples in lung disease…
Read moreA research team at Danderyd Hospital, led by Associate Professor Charlotte Thålin of Karolinska Institute, has initiated a pilot study using PExA’s non-invasive sampling technology. The aim is to analyze antibody responses in the lower airways – something that has previously not been possible without invasive procedures. Today’s vaccines generate a strong antibody response in…
Read morePExA AB, a Swedish life science company pioneering non-invasive lung research, has filed a patent application for a novel method that enables RNA fragmentomics analysis in exhaled air samples—a unique, non-invasive way to access molecular signals from the distal lung. Developed in collaboration with Sweden-based Precision BioAnalytics using RealSeq Biosciences’ proprietary RNA fragmentomics platform, the…
Read morePExA AB, a Swedish life science company and pioneer in non-invasive lung research, will participate in the American Thoracic Society (ATS) 2025 International Conference, taking place May 16–21 in San Francisco, California. Returning for the third consecutive year, PExA will exhibit at ATS — the world’s leading event for pulmonary, critical care, and sleep medicine. At Booth…
Read morePExA AB, a Swedish life science company and pioneer in non-invasive lung research, today announces a refined strategic direction to translate scientific advances into clinical solutions for early diagnosis and treatment monitoring of lung diseases. In recent years, PExA has focused on advancing its method and leveraging major developments in biochemical analysis. These advances have…
Read more
